Compare Biogen Inc (BIIB) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Biogen Inc trades at $196 (market cap $28.34B), while State Street Real Estate Select Sector SPDR ETF trades at $44.55. Which is the better fit depends on your goals.
| BIIB | XLRE | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.63 | $45.36 |
52-Week Low | $122.68 | $40.01 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
XLRE, the Real Estate Select Sector SPDR ETF, trades at $44.70 with a 0.56% daily gain, reflecting positive momentum amid a broader real estate sector recovery. Technical indicators show a bullish moving average consensus while oscillators remain neutral. The ETF's low 0.08% expense ratio and 3.4% dividend yield provide cost-efficient real estate exposure. Recent news highlights REITs defying rate pressures with strong 2026 performance, though inflation and Treasury yield volatility remain headwinds.
The outlook for XLRE appears cautiously optimistic as real estate fundamentals improve with steady NOI growth and declining supply. Key opportunities include attractive valuations and potential rate stability, while risks center on interest rate sensitivity and economic slowdowns. With technical strength and sector tailwinds, XLRE offers diversified real estate exposure but requires monitoring of Federal Reserve policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
